http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10087144-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82720f0fe09c6d788db8fde9be2350dc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate | 2016-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03838f6c1eeff72bee76828a6ab428e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5a4112add5aac19b68723576485d54a |
| publicationDate | 2018-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10087144-B2 |
| titleOfInvention | Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 H)-quinolone |
| abstract | The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: n n n n n n n n n n n n wherein: n n n V is N or CR 3 ; n X is N or CR 4 ; n Y is N or CR 5 ; n Z is N or CR 6 ; n B is —(C═O)R 1 , a 5- to 10-membered heteroaryl group, or a group n L′″-NRR′, wherein R and R′ are the same or different and each represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group; n R 1 is a 5- to 10-membered heterocyclyl group, or —OR′, wherein R′ is a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group, or R 1 is a proteinogenic α amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the α amino group, which amino acid is optionally esterified at the α carboxylic acid group with a C 1 -C 6 alkyl group or a C 6 -C 10 aryl group, or R 1 is —NR″R′″, —NR IV -L′″-CONR″R′″, or —NR IV -L′″-COOR, wherein R, R″, R′″ and R IV are the same or different and each represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 haloalkyl group; n either (a) W is N and R 9 and R 2 together form a bond, or (b) W is CR 8 , R 8 and R 9 together form a bond and R 2 is a hydrogen atom, or a C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, 5- to 10-membered heterocyclyl, -L′-A 2 , C 3 -C 10 cycloalkyl, or —COOR′ group, wherein R′ is a hydrogen atom or C 1 -C 6 alkyl group, or, when Z is a moiety CR 6 , R 2 may form, together with R 6 and the carbon and nitrogen atoms which connect R 2 and R 6 in the formula (I), a 5- to 6-membered heterocyclic ring; n R 3 is a hydrogen atom, a halogen atom, or a hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, nitro, or —NR′R″ group, wherein R′ and R″ are the same or different and each represent a hydrogen atom or C 1 -C 6 alkyl group; n R 4 and R 5 are the same or different and each represent a hydrogen atom, a halogen atom, or a hydroxyl, C 1 -C 8 alkyl, C 1 -C 8 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, nitro, —NR′R″, —CO 2 R′″, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, 5 to 10-membered heterocyclyl, or —CO—(C 1 -C 6 alkyl) group, wherein R′, R″ and R′″ are the same or different and each represent a hydrogen atom or C 1 -C 6 alkyl group, or R 4 and R 5 and the carbon atoms bonded to R 4 and R 5 together form a 5- to 6-membered heterocyclic ring; n R 6 is a hydrogen atom, a halogen atom, or a C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy or —CO 2 R′ group, wherein R′ is hydrogen or C 1 -C 6 alkyl, or, when W is a moiety CR 8 , R 6 may form, together with R 2 and the carbon and nitrogen atoms which connect R 6 and R 2 in the formula (I), a 5- to 6-membered heterocyclic ring; n R 7 is a hydrogen atom, a halogen atom, or a C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl group, n A 2 represents a C 6 -C 10 aryl or 5- to 10-membered heteroaryl group; n L′, and L′″ are the same or different and each represent a C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene group; n said aryl, heteroaryl, cycloalkyl and heterocyclyl groups being unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 hydroxyalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, —SOR, —SO 2 R, —NR′R″, —NR′(C═O)R″, —COOR, nitro and cyano substituents, wherein R, R′ and R″ are the same or different and each represents a hydrogen atom or C 1 -C 4 alkyl group. |
| priorityDate | 2014-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1421.